|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhatnagar N, Li X, Padi SK, Zhang Q, Tang
MS and Guo B: Downregulation of miR-205 and miR-31 confers
resistance to chemotherapy-induced apoptosis in prostate cancer
cells. Cell Death Dis. 1:e1052010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated
colorectal cancer invasion and metastasis. J Clin Invest.
124:1853–1867. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi N, Park J, Lee JS, Yoe J, Park GY,
Kim E, Jeon H, Cho YM, Roh TY and Lee Y:
miR-93/miR-106b/miR-375-CIC-CRABP1: A novel regulatory axis in
prostate cancer progression. Oncotarget. 6:23533–23547. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fujita Y, Kojima K, Ohhashi R, Hamada N,
Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T and Ito
M: MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Puhr M, Hoefer J, Schäfer G, Erb HH, Oh
SJ, Klocker H, Heidegger I, Neuwirt H and Culig Z:
Epithelial-to-mesenchymal transition leads to docetaxel resistance
in prostate cancer and is mediated by reduced expression of
miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi GH, Ye DW, Yao XD, Zhang SL, Dai B,
Zhang HL, Shen YJ, Zhu Y, Zhu YP, Xiao WJ and Ma CG: Involvement of
microRNA-21 in mediating chemo-resistance to docetaxel in
androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin.
31:867–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Lieberman R, Pan J, Zhang Q, Du M,
Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, et al: miR-375
induces docetaxel resistance in prostate cancer by targeting SEC23A
and YAP1. Mol Cancer. 15:702016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Card DA, Hebbar PB, Li L, Trotter KW,
Komatsu Y, Mishina Y and Archer TK: Oct4/Sox2-regulated miR-302
targets cyclin D1 in human embryonic stem cells. Mol Cell Biol.
28:6426–6438. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu H, Deng S, Zhao Z, Zhang H, Xiao J,
Song W, Gao F and Guan Y: Oct4 regulates the miR-302 cluster in P19
mouse embryonic carcinoma cells. Mol Biol Rep. 38:2155–2160. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu
DT, Chen DT and Ying SY: Mir-302 reprograms human skin cancer cells
into a pluripotent ES-cell-like state. RNA. 14:2115–2124. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bourguignon LY: Matrix hyaluronan promotes
specific MicroRNA upregulation leading to drug resistance and tumor
progression. Int J Mol Sci. 17:5172016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bourguignon LY, Wong G, Earle C and Chen
L: Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes
miR-302 expression leading to self-renewal, clonal formation, and
cisplatin resistance in cancer stem cells from head and neck
squamous cell carcinoma. J Biol Chem. 287:32800–32824. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Zhao L, Xiao Q, Jiang L, He M, Bai
X, Ma M, Jiao X and Wei M: miR-302a/b/c/d cooperatively inhibit
BCRP expression to increase drug sensitivity in breast cancer
cells. Gynecol Oncol. 141:592–601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao L, Wang Y, Jiang L, He M, Bai X, Yu L
and Wei M: MiR-302a/b/c/d cooperatively sensitizes breast cancer
cells to adriamycin via suppressing P-glycoprotein(P-gp) by
targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res.
35:252016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subramanyam D, Lamouille S, Judson RL, Liu
JY, Bucay N, Derynck R and Blelloch R: Multiple targets of miR-302
and miR-372 promote reprogramming of human fibroblasts to induced
pluripotent stem cells. Nat Biotechnol. 29:443–448. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lipchina I, Studer L and Betel D: The
expanding role of miR-302-367 in pluripotency and reprogramming.
Cell Cycle. 11:1517–1523. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin SL and Ying SY: Mechanism and method
for generating tumor-free iPS cells using intronic microRNA miR-302
induction. Methods Mol Biol. 936:295–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Yao J, Shi X, Hu L, Li Z, Song T
and Huang C: MicroRNA-302b suppresses cell proliferation by
targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells.
BMC Cancer. 13:4482013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Yao J, Zhang X, Guo B, Le X,
Cubberly M, Li Z, Nan K, Song T and Huang C: miRNA-302b suppresses
human hepatocellular carcinoma by targeting AKT2. Mol Cancer Res.
12:190–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang Y, Ahmed M, Guo H, Soares F, Hua JT,
Gao S, Lu C, Poon C, Han W, Langstein J, et al: LSD1-mediated
epigenetic reprogramming drives CENPE expression and prostate
cancer progression. Cancer Res. 77:5479–5490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gupta S, Weston A, Bearrs J, Thode T,
Neiss A, Soldi R and Sharma S: Reversible lysine-specific
demethylase 1 antagonist HCI-2509 inhibits growth and decreases
c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Prostate Cancer Prostatic Dis. 19:349–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noguchi K, Katayama K, Mitsuhashi J and
Sugimoto Y: Functions of the breast cancer resistance protein
(BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 61:26–33. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van der Kolk DM, Vellenga E, Scheffer GL,
Müller M, Bates SE, Scheper RJ and de Vries EG: Expression and
activity of breast cancer resistance protein (BCRP) in de novo and
relapsed acute myeloid leukemia. Blood. 99:3763–3770. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Breedveld P, Beijnen JH and Schellens JH:
Use of P-glycoprotein and BCRP inhibitors to improve oral
bioavailability and CNS penetration of anticancer drugs. Trends
Pharmacol Sci. 27:17–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Benadiba M, Dos Santos RR, Silva Dde O and
Colquhoun A: Inhibition of C6 rat glioma proliferation by
[Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and
mitochondrial membrane potential. J Inorg Biochem. 104:928–935.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sa G and Das T: Anti cancer effects of
curcumin: Cycle of life and death. Cell Div. 3:142008. View Article : Google Scholar : PubMed/NCBI
|
